ライフサイエンスコーパス: ritonavir

1 darunavir, and lopinavir (administered with ritonavir).

2 previr with JNJ-56914845 60 mg and TMC647055/ritonavir.

3 tched from lopinavir/ritonavir to atazanavir/ritonavir.

4 ceived darunavir/ritonavir and 44% lopinavir/ritonavir.

5 re total and subcutaneous fat than darunavir/ritonavir.

6 udine/lamivudine and nelfinavir or lopinavir/ritonavir.

7 nd use of empirical treatment with lopinavir-ritonavir.

8 plemental oxygen were treated with lopinavir-ritonavir.

9 at least one dose of darunavir boosted with ritonavir.

10 All subjects received darunavir 800 mg, ritonavir 100 mg, and emtricitabine 200 mg daily.

11 l ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus twice-daily oral dasabuvir 250 mg

12 ed protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clini

13 dolutegravir 50 mg or darunavir 800 mg plus ritonavir 100 mg, with investigator-selected combination

14 afety of darunavir (800 mg once per day) and ritonavir (100 mg once per day) plus either raltegravir

15 bitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily for 12 weeks (without cirr

16 to switch to darunavir (400 mg) boosted with ritonavir (100 mg) once daily or remain on ritonavir-boo

17 g administration of atazanavir (300 mg) plus ritonavir (100 mg) or lopinavir/ritonavir (800/200 mg) w

18 svir (25 mg) plus paritaprevir (150 mg) plus ritonavir (100 mg) with or without weight-based ribaviri

19 ibitor monotherapy (PI-mono); we recommended ritonavir (100 mg)-boosted darunavir (800 mg) once daily

20 mg)-boosted darunavir (800 mg) once daily or ritonavir (100 mg)-boosted lopinavir (400 mg) twice dail

21 ombitasvir (25 mg once daily), paritaprevir/ritonavir (150/100 mg once daily), and dasabuvir (250 or

22 Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1:

23 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day;

24 ; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 7

25 adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg i

26 tonavir (800/100 mg once daily) or lopinavir/ritonavir (400/100 mg twice daily) monotherapy, fasting

27 ART included lopinavir/ritonavir (400/100 mg) twice daily and emtricitabine/ten

28 ive oral ritonavir-boosted lopinavir (100 mg ritonavir, 400 mg lopinavir) plus 400 mg raltegravir twi

29 Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Ar

30 atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg in combination with tenofovir/emtri

31 es/mL during >/=6 months on stable darunavir/ritonavir (800/100 mg once daily) or lopinavir/ritonavir

32 300 mg) plus ritonavir (100 mg) or lopinavir/ritonavir (800/200 mg) with the 3D regimen is not recomm

33 eptibility to etravirine (78%) and darunavir/ritonavir (97%).

34 he basis of our investigations of analogs of ritonavir, a potent CYP3A4 inactivator and pharmacoenhan

35 ree regimen of ombitasvir, paritaprevir, and ritonavir, achieved high rates of SVR12 in patients with

36 bitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without

37 bitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks.

38 combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir, led to an SVR12

39 As a result, ritonavir adopts a distinctly different conformation to

40 n starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (9

41 cation complex inhibitor), paritaprevir, and ritonavir (an NS3/4A protease inhibitor)-an interferon-

42 s or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fum

43 4 received ombitasvir plus paritaprevir plus ritonavir and 42 received ombitasvir plus paritaprevir p

44 46 subjects enrolled, 56% received darunavir/ritonavir and 44% lopinavir/ritonavir.

45 Seven patients discontinued atazanavir/ritonavir and 5 discontinued darunavir/ritonavir due to

46 At 96 weeks, 56 (62%) atazanavir/ritonavir and 62 (71%) darunavir/ritonavir patients rema

47 l [CI], -.6 to 21.6) and 71 (79%) atazanavir/ritonavir and 75 (85%) darunavir/ritonavir patients rema

48 day) or ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day), both with inves

49 ound no major differences between atazanavir/ritonavir and darunavir/ritonavir in efficacy, clinicall

50 city of the side group analogous to Phe-2 of ritonavir and demonstrated the leading role of hydrophob

51 ition of testosterone 6beta-hydroxylation by ritonavir and indinavir.

52 fection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currentl

53 nue therapy (n = 128) or switch to darunavir/ritonavir and lamivudine (n = 129).

54 oninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with

55 Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therap

56 However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recom

57 ly after the use of acetaminophen, lopinavir/ritonavir and remdesivir, which are potentially hepatoto

58 Hydrogen bonding between ritonavir and SBA-15 surface silanols drives adsorption

59 mmunoglobulin, hydroxychloroquine, lopinavir/ritonavir, and broad-spectrum antibiotics, she ultimatel

60 exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respective

61 azithromycin, high-dose steroids, lopinavir/ritonavir, and tocilizumab.

62 P = .0362) increased more in the atazanavir/ritonavir arm than in darunavir/ritonavir arm.

63 Body fat changes in the atazanavir/ritonavir arm were associated with higher insulin resist

64 e atazanavir/ritonavir arm than in darunavir/ritonavir arm.

65 increase in triglycerides in the atazanavir/ritonavir arm.

66 o characterize the adsorption of hydrophobic ritonavir (as a model poorly water-soluble drug) to OMS

67 ovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or ralte

68 rate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

69 rate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or ralte

70 o determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral thera

71 nz-based ART (n=25), or receiving atazanavir-ritonavir-based ART (n=24).

72 the IMPAACT P1030 trial receiving lopinavir-ritonavir-based cART.

73 8 and randomly assigned to receive lopinavir/ritonavir-based or efavirenz-based ART.

74 virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia.

75 te ratio 1.14 [95% CI 1.10-1.19], p<0.0001), ritonavir-boosted atazanavir (1.20 [1.13-1.26], p<0.0001

76 600 mg once daily, or 1200 mg once daily or ritonavir-boosted atazanavir (300 mg of atazanavir and 1

77 (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial pair

78 sess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-booste

79 nd n=50 for the 1200 mg once daily group) or ritonavir-boosted atazanavir (n=51).

80 As secondary outcomes, efavirenz or ritonavir-boosted atazanavir concentrations were assesse

81 roups and two (4%) of the 51 patients in the ritonavir-boosted atazanavir group discontinued because

82 instances with no dose relation and for the ritonavir-boosted atazanavir group these were mostly gas

83 ups and five (10%) of the 51 patients in the ritonavir-boosted atazanavir group.

84 compared with 38 (75%) of 51 patients in the ritonavir-boosted atazanavir group.

85 68 groups and 14 (27%) of 51 patients in the ritonavir-boosted atazanavir group.

86 By contrast, participants receiving ritonavir-boosted atazanavir had 71% higher etonogestrel

87 ment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravi

88 lines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopina

89 avir group) or a three-tablet combination of ritonavir-boosted atazanavir plus coformulated tenofovir

90 with a boosted protease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and teno

91 il fumarate (integrase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and teno

92 ised that ART containing either efavirenz or ritonavir-boosted atazanavir would alter plasma concentr

93 In a comparison with ritonavir-boosted atazanavir, efficacy and safety of BMS

94 f exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopin

95 e exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavi

96 nd 51 patients received at least one dose of ritonavir-boosted atazanavir.

97 r therapy, to doravirine (100 mg per day) or ritonavir-boosted darunavir (100 mg ritonavir and 800 mg

98 diagnosed with INSTI-R virus, they change to ritonavir-boosted darunavir (DRV/r)-based ART.

99 e of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).

100 lvitegravir (EVGcobi), rilpivirine (RPV), or ritonavir-boosted darunavir (DRVrtv).

101 e randomly assigned to doravirine (n=385) or ritonavir-boosted darunavir (n=384), and 383 in both gro

102 15, 2017, 148 participants were assigned to ritonavir-boosted darunavir 400 mg and 152 continued on

103 define the non-inferiority of doravirine to ritonavir-boosted darunavir at 96 weeks.

104 Pilot studies suggest that ritonavir-boosted darunavir could show high efficacy at

105 lutegravir group and 164 (68%) of 242 in the ritonavir-boosted darunavir group had HIV-1 RNA less tha

106 ] in the doravirine group vs 91 [24%] in the ritonavir-boosted darunavir group), nausea (45 [12%] vs

107 doravirine group and one (<1%) of 383 in the ritonavir-boosted darunavir group.

108 Low-dose ritonavir-boosted darunavir might be a safe and efficaci

109 ological response rate than did those taking ritonavir-boosted darunavir once daily, with similar tol

110 avir-boosted darunavir plus raltegravir; B2, ritonavir-boosted darunavir plus raltegravir plus etravi

111 ricitabine or tenofovir plus lamivudine), C (ritonavir-boosted darunavir plus raltegravir plus tenofo

112 amivudine), and D (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir) were defin

113 everse transcriptase inhibitors [NRTIs] plus ritonavir-boosted darunavir plus raltegravir; B2, ritona

114 ntiretrovirals (raltegravir, etravirine, and ritonavir-boosted darunavir) and diagnostic monitoring t

115 ive dolutegravir and 242 assigned to receive ritonavir-boosted darunavir).

116 unavir plus raltegravir plus etravirine; B3, ritonavir-boosted darunavir, raltegravir, and either ten

117 itor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profi

118 concluded that dolutegravir was superior to ritonavir-boosted darunavir.

119 virological response rate than is once-daily ritonavir-boosted darunavir.

120 e curve increased >4-fold in the presence of ritonavir-boosted HIV protease inhibitors, while pibrent

121 atazanavir (1.20 [1.13-1.26], p<0.0001), and ritonavir-boosted lopinavir (1.11 [1.06-1.16], p<0.0001)

122 were randomly assigned (1:1) to receive oral ritonavir-boosted lopinavir (100 mg ritonavir, 400 mg lo

123 h ritonavir (100 mg) once daily or remain on ritonavir-boosted lopinavir (800 mg [plus 200 mg ritonav

124 eive oral dolutegravir (50 mg once daily) or ritonavir-boosted lopinavir (800 mg lopinavir plus 200 m

125 show equivalent efficacy to continuation of ritonavir-boosted lopinavir (a protease inhibitor common

126 ching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic contro

127 not boys) exposed in utero to ZDV/lamivudine/ritonavir-boosted lopinavir (LPV/r) had a higher left ve

128 ull hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (P < .001) for both end poin

129 ng of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse tra

130 sed trial showed that NtRTI-sparing ART with ritonavir-boosted lopinavir and raltegravir (raltegravir

131 vir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and two or three NtRTIs (NtR

132 with two NRTIs, dolutegravir was superior to ritonavir-boosted lopinavir at 48 weeks and can be consi

133 -treatment for tuberculosis, preservation of ritonavir-boosted lopinavir for second-line treatment, a

134 ession compared with 219 (70%) of 312 in the ritonavir-boosted lopinavir group (adjusted difference 1

135 ned to the dolutegravir group (n=312) or the ritonavir-boosted lopinavir group (n=315).

136 Three patients in the ritonavir-boosted lopinavir group did not receive study

137 he efavirenz group and 0.284 (n = 42) in the ritonavir-boosted lopinavir group.

138 the efavirenz group and 0.020 (n = 3) in the ritonavir-boosted lopinavir group.

139 %) higher in the efavirenz group than in the ritonavir-boosted lopinavir group.

140 ipants were 18 years or older, who tolerated ritonavir-boosted lopinavir in combination with two nucl

141 g, our data support WHO's recommendation for ritonavir-boosted lopinavir plus NRTI for second-line an

142 Ritonavir-boosted lopinavir plus raltegravir is an appro

143 gravir twice a day (raltegravir group) or to ritonavir-boosted lopinavir plus two or three NRTIs sele

144 -4 drug-related adverse events occurred with ritonavir-boosted lopinavir than dolutegravir (44 [14%]

145 l fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy.

146 avir than dolutegravir (44 [14%] of 310 with ritonavir-boosted lopinavir vs 11 [4%] of 314 with dolut

147 boosted protease inhibitor (standardised to ritonavir-boosted lopinavir) with two to three NRTIs (cl

148 iptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitor

149 Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or

150 oxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir-boosted pro

151 y and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse

152 favirenz-based therapy (n = 150) or continue ritonavir-boosted lopinavir-based therapy (n = 148).

153 irenz-based therapy compared with continuing ritonavir-boosted lopinavir-based therapy did not result

154 sion and with initial viral suppression with ritonavir-boosted lopinavir-based therapy, switching to

155 sma HIV RNA of less than 50 copies/mL during ritonavir-boosted lopinavir-based therapy; 298 were rand

156 egravir was favourable compared with that of ritonavir-boosted lopinavir.

157 icipants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg w

158 nd first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavi

159 To determine whether treatment with ritonavir-boosted protease inhibitor (PI) monotherapy is

160 Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regime

161 o switch to a strategy of physician-selected ritonavir-boosted protease inhibitor monotherapy (PI-mon

162 side reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paire

163 d-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents

164 de Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Protease Inhibitors (PI) with the same

165 ammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs).

166 (1.11 [1.06-1.16], p<0.0001), but not other ritonavir-boosted protease inhibitors or abacavir.

167 azanavir, ritonavir-boosted lopinavir, other ritonavir-boosted protease inhibitors, or abacavir.

168 counts, and those who had received lopinavir/ritonavir, but was lower among prior nevirapine recipien

169 Associations between ritonavir C24 and lipid changes at week 48 were evaluate

170 Ritonavir C24 was not different by arm (P = .89) (median

171 Ritonavir C24 was not different in the PI arms and had n

172 Comparison with the CYP3A5-ritonavir complex confirmed conserved CYP3A5 structural

173 ously shown that the structure of the CYP3A5-ritonavir complex differs substantially from that of the

174 iffers substantially from that of the CYP3A4-ritonavir complex.

175 een CYP3A4 and CYP3A5 that favor alternative ritonavir conformations.

176 vudine, raltegravir, rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, or

177 roxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL).

178 nofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.

179 onate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (R

180 - ribavirin (9%) and ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (6%).

181 with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was effi

182 In contrast, for ombitasvir/paritaprevir/ritonavir +/- dasabuvir potentially significant DDIs cou

183 Ombitasvir-paritaprevir-ritonavir-dasabuvir may cause type B lactic acidosis.

184 d had started taking ombitasvir-paritaprevir-ritonavir-dasabuvir within the preceding 2 weeks, presen

185 rting treatment with ombitasvir-paritaprevir-ritonavir-dasabuvir.

186 asvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir during the 18-month period from Janu

187 buvir/velpatasvir (SIMPLIFY) or paritaprevir/ritonavir/dasabuvir/ombitasvir +/- ribavirin (D3FEAT) fo

188 previr; sofosbuvir; ombitasvir, paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatas

189 our of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, a

190 rated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase

191 ese trials were compared with darunavir plus ritonavir (DRV+r) in DRIVE-FORWARD and efavirenz (EFV) i

192 plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

193 plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s,

194 plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL).

195 navir/ritonavir and 5 discontinued darunavir/ritonavir due to adverse effects.

196 se transport with the HIV protease inhibitor ritonavir elicited growth arrest and/or apoptosis in mul

197 glucose metabolism with the GLUT4 inhibitor ritonavir elicits variable cytotoxicity in MM that is ma

198 However, owing to higher paritaprevir and/or ritonavir exposures, evening administration of atazanavi

199 Extensive adsorption of ritonavir from solution by mesoporous SBA-15 silica was

200 ritonavir (ombitasvir plus paritaprevir plus ritonavir), given with or without ribavirin.

201 ir group and 13 (four) in the darunavir plus ritonavir group discontinued because of adverse events.

202 group vs 57/242 [24%] in the darunavir plus ritonavir group), nausea (31/242 [13%] vs 34/242 [14%]),

203 nds (15a and 15b) that are less complex than ritonavir have comparable submicromolar affinity and inh

204 ations used in COVID-19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir, and tocilizum

205 A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.

206 is capable of detecting 100 ppm crystalline ritonavir in an amorphous hydroxypropyl methylcellulose

207 s between atazanavir/ritonavir and darunavir/ritonavir in efficacy, clinically relevant side effects,

208 Ketoconazole, clotrimazole, ritonavir, indinavir, and itraconazole are strong inhibi

209 Lopinavir, but not ritonavir, inhibited CYP17A1 and CYP21A2 activity in H29

210 east one of six drugs (remdesivir, lopinavir-ritonavir, interferon beta, corticosteroids, chloroquine

211 were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids.

212 ical trial comparing nevirapine to lopinavir/ritonavir (International Maternal Pediatric Adolescent A

213 ecombinant interferon beta-1b plus lopinavir-ritonavir (intervention) or placebo for 14 days.

214 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus ge

215 However, atazanavir/ritonavir led to higher triglycerides and more total and

216 recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among pati

217 PIs (ritonavir, lopinavir, and atazanavir) but not nucleoside

218 2.40), per 5 years of exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil

219 rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabi

220 xposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease i

221 in comparison with treatment with lopinavir/ritonavir (LPV/r) alone.

222 al components by 2.1- to 3.4-fold; lopinavir/ritonavir (LPV/r) increased lumefantrine exposure by 2.1

223 erinatal treatment with lopinavir boosted by ritonavir (LPV/r) is associated with steroidogenic abnor

224 Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failur

225 nstrated short-term superiority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretrovira

226 Three randomized trials compared lopinavir/ritonavir (LPV/r) to nevirapine (NVP) for antiretroviral

227 ranscriptase inhibitor (NNRTI)- or lopinavir/ritonavir (LPV/r)-based regimen were enrolled.

228 regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%-98.6%; TDF+FTC+r

229 Calpain inhibition by ritonavir may be a powerful tool for preserving neurons

230 riptase inhibitors associated with darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and ma

231 ith darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and maraviroc (n = 3).

232 Treatments of these foam cells with ritonavir, nelfinavir, and saquinavir at least doubled c

233 ta analysis framework, 3 commonly used ARTs (ritonavir, nelfinavir, and saquinavir) were found alteri

234 50), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir),

235 with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, con

236 study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/s

237 35S, a substudy of trial A5329 (paritaprevir/ritonavir, ombitasvir, dasabuvir, with ribavirin) that e

238 ical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or witho

239 HCV treatment with paritaprevir-ritonavir-ombitasvir plus dasabuvir is highly effective

240 vir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment o

241 asvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice daily) +/- ribavi

242 asvir (once-daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice-daily) +/-ribavir

243 h to 400 mg of darunavir boosted with 100 mg ritonavir once daily could show equivalent efficacy to c

244 sted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily),

245 azanavir (300 mg of atazanavir and 100 mg of ritonavir once daily), each with 400 mg of raltegravir t

246 ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir once daily, with weight-based ribavirin dosed

247 nase occurred in combination with atazanavir/ritonavir only.

248 respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor.

249 ir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoprox

250 itabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL).

251 plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.

252 ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir orally once daily plus weight-based ribavirin.

253 atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before base

254 ed using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvir to treat: (1) any patie

255 atazanavir/ritonavir and 62 (71%) darunavir/ritonavir patients remained free of treatment failure (e

256 atazanavir/ritonavir and 75 (85%) darunavir/ritonavir patients remained free of virological failure

257 ne compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human

258 DV/SOF +/- RBV) and ombitasvir/ paritaprevir/ritonavir plus dasabuvir (OPrD) +/- RBV in HIV/HCV genot

259 aclatasvir, or ombitasvir, paritaprevir, and ritonavir plus dasabuvir are suitable.

260 triple antiretroviral prophylaxis (lopinavir-ritonavir plus either lamivudine and zidovudine or emtri

261 Dual therapy with lopinavir and ritonavir plus lamivudine regimen warrants further clini

262 treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin beyond 12 weeks seems to have n

263 Ombitasvir, paritaprevir, and ritonavir plus ribavirin for 12 weeks achieved SVR12 in

264 treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin.

265 onavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 42

266 ir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV genotype

267 inistered as 150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin, the rate of sustained virolog

268 treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin in patients

269 d coformulated ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 12 wee

270 Treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 8 week

271 vir, an NS3/4A protease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV in

272 recombinant interferon beta-1b and lopinavir-ritonavir reduces mortality among patients hospitalized

273 ning atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination wi

274 2-DAA) combination of simeprevir + TMC647055/ritonavir +/- ribavirin and of the 3-DAA combination of

275 Ritonavir (RTV) and atazanavir (ATV) were co-formulated

276 Ritonavir (RTV) is on the World Health Organization's Li

277 granules and a fixed-dose combination of LPV/ritonavir (RTV) ISNP granules, were prepared using the I

278 ntiretroviral (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated

279 with atazanavir (ATV) with or without (+/-) ritonavir (RTV) or standard of care (SOC) (tenofovir dis

280 Treatment with lopinavir-ritonavir showed no significant benefit in mortality and

281 5; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31

282 ; or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based ART).

283 ults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledron

284 In contrast to ritonavir, the binding affinity of N-methylritonavir for

285 with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

286 Ritonavir treatment significantly reduced calpain activi

287 CTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24).

288 atio [aOR], 1.95; 95% CI, 1.24-3.05) and for ritonavir used as a booster (aOR, 1.56; 95% CI, 1.11-2.2

289 irus were treated with the FDA-approved drug ritonavir using a dosing regimen that resulted in plasma

290 and 3A5, the structure of 3A5 complexed with ritonavir was determined by X-ray crystallography to a l

291 Also, fat gains with atazanavir/ritonavir were associated with insulin resistance.

292 showed intermediate resistance to darunavir/ritonavir, whereas high-level resistance was not observe

293 CYP3A4 with N-methylritonavir, an analog of ritonavir, widely used as a pharmacoenhancer.

294 Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) +/- ribavirin

295 regimen of ombitasvir plus paritaprevir plus ritonavir with or without ribavirin achieved high sustai

296 2 received ombitasvir plus paritaprevir plus ritonavir with ribavirin, and 49 treatment-experienced p

297 bursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin

298 o slightly above the amorphous solubility of ritonavir, with the extent of drug adsorption increasing

299 navir-boosted lopinavir (800 mg [plus 200 mg ritonavir]), with nucleoside analogues left unchanged.

300 lone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricit